Tildrakizumab for treating moderate to severe plaque psoriasis

Tildrakizumab (Ilumetri, Almirall) has a marketing authorisation 'for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.'

Tildrakizumab is administered by subcutaneous injection at a dose of 100 mg at weeks 0 and 4 and every 12 weeks thereafter. In patients with certain characteristics (for example, high disease burden, body weight of 90 kg or more), a 200 mg dose may provide greater efficacy.

Consideration should be given to stopping treatment in patients whose psoriasis has shown no response after 28 weeks of treatment. An initial partial response may subsequently improve with continued treatment beyond 28 weeks.

The list price of tildrakizumab is £3,241 for both the 100 mg (single-dose pack of 1 prefilled syringe) and the 200 mg (single-dose pack of 2×100 mg prefilled syringes) doses (excluding VAT; price as quoted in company's submission).

The company has a commercial arrangement. This makes tildrakizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.